ReviewThe oncologist2017
Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.
Review in The oncologist, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 139 citations in OpenAlex.
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer.ESMO open · 2024Guideline
- Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.Nature medicine · 2020Trial
- Perioperative pancreatic ductal adenocarcinoma care in 2025: who needs neoadjuvant?-who needs radiation?Gland surgery · 2026Review
- Prognostic, Predictive, and Clinical Relevance of DNA Damage Repair Alterations in Biliary Tract Cancers.Cancers · 2026Review
- Advancing systemic therapy for biliary tract cancer: current strategies and emerging paradigms.Frontiers in oncology · 2026Review
- Rapid Development of Diffuse-Type Remnant Pancreatic Cancer Following Obstructive Pancreatitis after Pancreaticoduodenectomy for Distal Bile Duct Carcinoma: A Case Report.Surgical case reports · 2026Article
- The prognostic and predictive value of homologous recombination deficiency in gastrointestinal cancer.The oncologist · 2025Review
- Molecular Tumor Board-Guided Targeted Treatments for Biliary Tract Cancers in a Publicly Funded Healthcare System.Current oncology (Toronto, Ont.) · 2025Article
- The efficacy of olaparib as salvage therapy in an advanced intrahepatic cholangiocarcinoma patient harboring somaticFrontiers in pharmacology · 2025Article
- Chinese expert consensus on the clinical application of molecular diagnostics in hepatobiliary cancers (2024 edition).Liver research (Beijing, China) · 2024Article
- [Expert consensus for clinical application of molecular diagnosis on hepatobiliary tumors (2024 edition)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- ADAR1 promotes cisplatin resistance in intrahepatic cholangiocarcinoma by regulating BRCA2 expression through A-to-I editing manner.Cell proliferation · 2024Article
- Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer.Current treatment options in oncology · 2024Review
- Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma.Cancers · 2024Review
- Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine.Cancers · 2024Review
- Durable response to first-line PARP inhibition inJournal of gastrointestinal oncology · 2023Article
- ROR1-AS1 might promote in vivo and in vitro proliferation and invasion of cholangiocarcinoma cells.BMC cancer · 2023Article
- Unexpected finding of a rare pathogenic germline BRCA1 variant in an intrahepatic cholangiocarcinoma using the Oncomine Focus DNA assay: clinical and diagnostic implications.Molecular biology reports · 2023Article
- Article
- A case of unresectable intrahepatic cholangiocarcinoma with a germline BRCA1 mutation.Clinical journal of gastroenterology · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiliary tract malignancies, in particular cholangiocarcinomas (CCA), are rare tumors that carry a poor prognosis. MATERIALS AND
methodsWe performed a multicenter retrospective analysis of CCA patients diagnosed between January 2000 and December 2013 with GL or somatic variants in
resultsOverall, 18 cases were identified: 5 carriers of GL
conclusionBRCA-associated CCA is uncommon. This multicenter retrospective study provides a thorough clinical analysis of a BRCA-associated CCA cohort, which can serve as a benchmark for future development and design of expanded analyses and clinical trials. IMPLICATIONS FOR PRACTICE: BRCA-associated CCA is uncommon but a very important subtype of hepatic malignancies, due to its rising prevalence. Better clinical characterization of this subtype might allow application of targeted therapy for CCA patients with germline or somatic mutations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.